Massimo Bongiovanni1, William C Faquin2, Luca Giovanella3, Cosimo Durante4, Peter Kopp5, Pierpaolo Trimboli3. 1. Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, Lausanne, Switzerland. 2. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3. Department of Nuclear Medicine and Thyroid Centre, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. 4. Dipartimento di Medicina Traslazionale e di Precisione, Azienda Ospedaliera Universitaria Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy. 5. Service of Endocrinology, Diabetology and Metabolism, CHUV, Lausanne University Hospital, Lausanne, Switzerland.
Abstract
OBJECTIVE: The second version of The Bethesda System for Reporting Thyroid Cytopathology endorsed the introduction of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) as a distinct entity with low malignant potential into clinical practice. Consequently, the risk of malignancy (ROM) of cytological diagnoses has changed, but the magnitude of the change remains uncertain. The present systematic review was undertaken to obtain more robust information about the true impact of NIFTP on the ROM among patients undergoing surgery following a fine-needle aspiration cytology (FNAC) diagnosis of suspicious for malignancy (Bethesda V) or malignant (Bethesda VI). As they are managed surgically, these two diagnostic categories are the primary entities that are clinically impacted by the advent of NIFTP. DESIGN: Systematic review and meta-analysis. METHODS: A comprehensive literature search of online databases was performed in November 2018. The search was conducted looking for data of histologically proven NIFTP with preoperative FNAC. RESULTS: One-hundred fifty-seven articles were identified and nine were included in the study. Overall, there were 13,752 thyroidectomies with a cancer prevalence of 45.7%. When NIFTP was considered non-malignant, the pooled risk difference for ROM was 5.5%. Applying meta-analysis, the pooled prevalence of NIFTP among nodules with FNAC of Bethesda V or Bethesda VI was 14 and 3%, respectively. CONCLUSION: This meta-analysis shows that the inclusion of NIFTP leads to a reduction in the ROM for the Bethesda V and Bethesda VI FNAC diagnostic categories by 14 and 3%, respectively. Clinicians should be aware of these data to avoid overtreatment.
OBJECTIVE: The second version of The Bethesda System for Reporting Thyroid Cytopathology endorsed the introduction of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) as a distinct entity with low malignant potential into clinical practice. Consequently, the risk of malignancy (ROM) of cytological diagnoses has changed, but the magnitude of the change remains uncertain. The present systematic review was undertaken to obtain more robust information about the true impact of NIFTP on the ROM among patients undergoing surgery following a fine-needle aspiration cytology (FNAC) diagnosis of suspicious for malignancy (Bethesda V) or malignant (Bethesda VI). As they are managed surgically, these two diagnostic categories are the primary entities that are clinically impacted by the advent of NIFTP. DESIGN: Systematic review and meta-analysis. METHODS: A comprehensive literature search of online databases was performed in November 2018. The search was conducted looking for data of histologically proven NIFTP with preoperative FNAC. RESULTS: One-hundred fifty-seven articles were identified and nine were included in the study. Overall, there were 13,752 thyroidectomies with a cancer prevalence of 45.7%. When NIFTP was considered non-malignant, the pooled risk difference for ROM was 5.5%. Applying meta-analysis, the pooled prevalence of NIFTP among nodules with FNAC of Bethesda V or Bethesda VI was 14 and 3%, respectively. CONCLUSION: This meta-analysis shows that the inclusion of NIFTP leads to a reduction in the ROM for the Bethesda V and Bethesda VI FNAC diagnostic categories by 14 and 3%, respectively. Clinicians should be aware of these data to avoid overtreatment.
Authors: Mitsuyoshi Hirokawa; J Aidan Carney; John R Goellner; Ronald A DeLellis; Clara S Heffess; Ryohei Katoh; Masahiko Tsujimoto; Kennichi Kakudo Journal: Am J Surg Pathol Date: 2002-11 Impact factor: 6.394
Authors: Zubair W Baloch; Raja R Seethala; William C Faquin; Mauro G Papotti; Fulvio Basolo; Guido Fadda; Gregory W Randolph; Steven P Hodak; Yuri E Nikiforov; Susan J Mandel Journal: Cancer Cytopathol Date: 2016-05-20 Impact factor: 5.284
Authors: Ricardo V Lloyd; Sylvia L Asa; Virginia A LiVolsi; Peter M Sadow; Arthur S Tischler; Ronald A Ghossein; R Michael Tuttle; Yuri E Nikiforov Journal: Hum Pathol Date: 2018-01-16 Impact factor: 3.466
Authors: Ricardo R Lastra; George Birdsong; David H Hwang; Merce Jorda; Darcy A Kerr; Cindy McGrath; Shelley Odronic; Rema Rao; Paul A VanderLaan; Joe W Walker; Tatjana Antic Journal: J Am Soc Cytopathol Date: 2017-12-21
Authors: Lester D R Thompson; David N Poller; Kennichi Kakudo; Raoul Burchette; Yuri E Nikiforov; Raja R Seethala Journal: Endocr Pathol Date: 2018-09 Impact factor: 3.943
Authors: Lorenzo Scappaticcio; Arnoldo Piccardo; Giorgio Treglia; David N Poller; Pierpaolo Trimboli Journal: Endocrine Date: 2021-03-24 Impact factor: 3.633